Life sciences · Journal article
Journal of the American Chemical Society · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Tumor-resident bacteria establish a profound immunosuppressive microenvironment that compromises cancer immunotherapy. While ablating these microbes holds therapeutic promise, broad-spectrum antibiotics can cause systemic dysbiosis, and the Gram-negative outer membrane can restrict the entry of conventional sonosensitizers, limiting the antibacterial efficacy of sonodynamic therapy (SDT). Here, we report an ultrasound-driven, bacteria-targeted immunotherapy utilizing polyarginine-functionalized peptide-sonosensitizer conjugates to achieve the in situ pulverization of the tumor Fusobacterium nucleatum (F. nucleatum), thereby eliciting potent innate antitumor immunity. The cationic conjugates electrostatically intercalate into Gram-negative bacterial membranes, inflicting a structural predisruption. Subsequent ultrasound irradiation synergizes localized sonochemical oxidation with mechanical shear forces to thoroughly shatter the bacteria. This targeted microbial fragmentation liberates massive quantities of pathogen-associated molecular patterns (PAMPs) that, unlike tumor-derived signals from conventional SDT, decisively reprogram macrophages toward an antitumor M1 phenotype to awaken innate immunity. Synchronized with tumor-specific antigens released via conjugate-induced immunogenic cell death, the liberated PAMPs synergistically amplify antigen presentation and optimally drive dendritic cell maturation. In a bacteria-colonized murine colorectal cancer model, this localized therapy markedly suppressed primary tumor growth and elicited both a pronounced abscopal effect against distant tumors and antitumor immune memory. By repurposing complicit bacteria into potent endogenous adjuvants, this ultrasound-driven strategy reverses bacteria-mediated immunosuppression, offering a transformative paradigm for treating microbiome-colonized solid tumors.